bioecon Member area
Technology · Services, governance & capital / Regulatory & legal

Medical-device reimbursement listing

Consultancies that secure CPT/HCPCS billing codes, payer coverage policies and national health-insurance listings for medical devices — turning FDA clearance into an actual reimbursement pathway that determines whether hospitals and clinicians will be paid to use the device.

Medicine & Pharmaceuticals Risk: low Medical devices & implants Diagnostics US · EU verified 2026-08-16 · 7 Sources (0 independent)

1 · What it gives

Medical-device reimbursement listing is a B2B services category in which specialist consultancies secure the CPT/HCPCS billing codes, payer coverage policies and national health-insurance listings a medical device needs to be paid for in clinical use — a step distinct from, and often more commercially decisive than, FDA clearance itself. MCRA runs a dedicated regulatory and reimbursement consulting practice supporting medical device companies through both FDA 510(k) submission and CPT/HCPCS coding strategy. Avalere Health integrates clinical, coding and reimbursement strategy from early development, arguing that early-integrated strategies transform market-access challenges into successful launches with clear coverage and payment pathways. Boston Strategic Partners combines business and clinical strategy with health-economics and outcomes research (HEOR) and medical/technical writing to support device reimbursement dossiers. Emergo by UL, a global QA/RA consulting firm, extends its FDA 510(k)/De Novo/PMA regulatory practice into the reimbursement-adjacent compliance work devices need alongside clearance. Real Endpoints is a market-access advisory firm focused specifically on commercial and private-payer coverage policy and prior-authorization navigation for medical devices. Vintura, based in the Netherlands, advises life-sciences clients on policy shaping and commercial strategy across European reimbursement systems, addressing the persistent gap between what a device or medicine can offer and what patients actually receive.

The key directions of medical-device reimbursement listing are:

  1. CPT/HCPCS coding strategy: securing or navigating the billing codes (Current Procedural Terminology, Healthcare Common Procedure Coding System) a device needs for a provider to bill for its use.
  2. Payer coverage-policy navigation: working with commercial insurers and public payers to establish a coverage policy under which the device is eligible for payment.
  3. Health-economics and outcomes research (HEOR): building the clinical and economic evidence dossier payers require to justify a coverage or reimbursement decision.
  4. European and national reimbursement-system policy shaping: advising on the specific health-technology-assessment and reimbursement-listing processes of individual national systems outside the US.

Sectoral value chain#

[FDA clearance/approval] ──> [CPT/HCPCS coding strategy] ──> [Payer coverage-policy submission]
                                                                    │
                                                        (HEOR evidence-dossier development)
                                                                    │
              [Ongoing coverage-policy monitoring] <──── [Reimbursement decision & listing] <─── [Payer review & negotiation]

Value chain levels#

LevelDescriptionKey inputs/outputs
Regulatory clearanceThe device receives FDA clearance or approval, the prerequisite before a reimbursement pathway can be pursued.In: Regulatory submission.
Out: Cleared/approved device.
Coding strategyDetermining and securing the CPT/HCPCS billing codes a provider needs to bill for the device’s use.In: Cleared/approved device, procedure description.
Out: Assigned or requested billing code.
Coverage-policy submissionSubmitting evidence to commercial and public payers to establish a coverage policy for the device.In: Billing code, clinical evidence.
Out: Coverage-policy submission.
Payer review and negotiationPayers review the submission, often requesting additional health-economics evidence before deciding.In: Coverage-policy submission.
Out: Payer review outcome.
Reimbursement decision and listingThe payer issues a coverage decision and, where applicable, the device is added to a formal reimbursement listing.In: Payer review outcome.
Out: Coverage decision, reimbursement listing.
Ongoing coverage-policy monitoringTracking payer coverage-policy changes and prior-authorization requirements that affect the device’s ongoing reimbursement status.In: Reimbursement listing.
Out: Maintained reimbursement status.

Cross-cutting technologies of the sector:

  • CPT/HCPCS coding strategy: the specific process of determining and securing the billing codes a medical device needs for a provider to be paid for its use.
  • Payer coverage-policy analytics: structured tracking and analysis of commercial and public payer coverage policies relevant to a specific device category.
  • Market-access consulting: integrated advisory services combining regulatory, coding, coverage and HEOR expertise to build a full reimbursement pathway.

2 · What it replaces 2 · matched by industry

D2E4Crop disease forecasting models, spore traps, pheromone and smart pest traps and field diagnostics — spray when risk is real instead of calendar-based fungicide and insecticide programmes
Replaces: Fixed-interval ("calendar") protective fungicide sprays and routine insecticide applications regardless of pest pressure
EAC
D2E–On-farm culture, PCR panels, rapid tests and veterinary laboratory services for livestock and aquaculture — treat what is diagnosed instead of blanket and prophylactic antibiotic treatment
Replaces: Blanket treatment of every clinical mastitis case, group metaphylaxis on suspicion, prophylactic antibiotics in hatcheries and ponds, …
DIAG

3 · How to implement 6 steps

  1. 1
    Regulatory clearanceRegulatory & certification
    The device receives FDA clearance or approval, the prerequisite step before a reimbursement pathway can be pursued.
    Registration in Russia / EAEU: EAC — EAEU accredited bodies / Rosakkreditatsiya
  2. 2
    CPT/HCPCS coding strategy
    The consultancy determines and secures the billing codes a provider needs to bill for the device’s use, requesting a new code where none exists.
  3. 3
    Coverage-policy submission
    Evidence supporting the device’s clinical and economic value is submitted to commercial and public payers to establish a formal coverage policy.
  4. 4
    Payer review and negotiation
    Payers review the submission, often requesting additional health-economics evidence or negotiating specific coverage terms before deciding.
  5. 5
    Reimbursement decision and listing
    The payer issues a coverage decision, and where applicable, the device is added to a formal reimbursement listing that providers can bill against.
  6. 6
    Ongoing coverage-policy monitoring
    The consultancy tracks payer coverage-policy changes and prior-authorization requirements that could affect the device’s ongoing reimbursement status.

4 · Who delivers

Matched suppliers (matched automatically)

Boston ScientificUnited StatesProduceractive
Giant Biogene HoldingChinaDistributoractive
KanekaJapanProduceractive
Saber Chemical, Inc.United StatesProduceractive
EcoWin (Dong-A ST sub)South KoreaResearch / RTOactive
DaicelJapanProduceractive
Tsingke BiotechnologyChinaProduceractive
China Resources PharmaceuticalHong KongProduceractive
Longevity Center EuropePolandServices / consultingactive
BioYomeIsraelProduceractive

In the services and supply catalogue 2 · paid service

Consulting & market access · Regulatory & certification

Leading companies and institutes (from the brief)

Company / InstituteCountryKey products / platformsTech featuresStatus 2026
MCRA🇺🇸 USARegulatory + reimbursement consultingCombined FDA 510(k) and CPT/HCPCS practicecommercial
Avalere Health🇺🇸 USAIntegrated market-access advisoryClinical/coding/reimbursement strategycommercial
Boston Strategic Partners🇺🇸 USABusiness & clinical strategyHEOR and medical/technical writingcommercial
Emergo by UL🇺🇸 USAGlobal QA/RA consultingFDA 510(k)/De Novo/PMA-adjacent reimbursement workcommercial
Real Endpoints🇺🇸 USAPayer-coverage advisoryCommercial/private-payer coverage focuscommercial
Vintura🇳🇱 NetherlandsEuropean market-access consultingPolicy shaping across EU reimbursement systemscommercial

5 · Rules & route to market

Route into Russia / EAEU: EAC · EAEU accredited bodies / Rosakkreditatsiya
declaration registered within 3 working days (testing extra); certification longer
Information, not legal advice — confirm the procedure for your product. (2026-10-06)
United States

The United States hosts the largest concentration of medical-device reimbursement consultancies, several combining FDA regulatory practices with dedicated coding and payer-coverage expertise.

MCRA’s combined regulatory-reimbursement practice, Avalere’s integrated coding strategy, Boston Strategic Partners’ HEOR support, Emergo by UL’s global QA/RA-adjacent work, Real Endpoints’ payer-coverage focus#

  • MCRA: runs a dedicated regulatory and reimbursement consulting practice supporting medical device companies through both FDA 510(k) submission and CPT/HCPCS coding strategy.
  • Avalere Health: integrates clinical, coding and reimbursement strategy from early development, transforming market-access challenges into launches with clear coverage and payment pathways.
  • Boston Strategic Partners: combines business and clinical strategy with health-economics and outcomes research and medical/technical writing to support device reimbursement dossiers.
  • Emergo by UL: a global QA/RA consulting firm extending its FDA 510(k)/De Novo/PMA regulatory practice into the reimbursement-adjacent compliance work devices need alongside clearance.
  • Real Endpoints: a market-access advisory firm focused specifically on commercial and private-payer coverage policy and prior-authorization navigation for medical devices.

European Union

Europe hosts market-access and policy-shaping consultancies working across the fragmented national health-technology-assessment and reimbursement-listing systems of individual EU member states.

Vintura’s policy-shaping and commercial-strategy practice across European reimbursement systems#

  • Vintura: based in the Netherlands, advises life-sciences clients on policy shaping and commercial strategy across European reimbursement systems, addressing the persistent gap between what a device can offer and what patients actually receive under national coverage decisions.

China

China is covered qualitatively rather than through a live-screened Chinese vendor: candidate Chinese medical-device reimbursement consultancies searched during this screen returned no confirming 2026 source, so no Chinese company is tabled below. Medical-device reimbursement listing in China runs through the National Healthcare Security Administration’s centralized procurement and medical-insurance catalog processes rather than the payer-by-payer model common in the US and Europe, and specialist consulting practices supporting this process could not be confirmed in this screen.

China’s centralized medical-insurance listing process without a confirmed specialist consultancy#

  • Centralized listing model: device reimbursement in China runs through the National Healthcare Security Administration’s centralized procurement and medical-insurance catalog listing process, structurally distinct from the multi-payer US model.
  • Domestic gap: no Chinese-headquartered medical-device reimbursement consultancy confirmed by a live 2026 source was found during this screen.

6 · Money: tenders & grants

7 · Tech stack & innovations

The medical-device reimbursement listing stack combines regulatory-adjacent coding expertise with structured payer-coverage analytics and health-economics evidence development:

  1. CPT/HCPCS coding strategy:
    • Firms such as MCRA and Avalere Health determine and secure the specific billing codes a device needs, a step that directly determines whether providers can be paid for using it.
  2. Payer coverage-policy analytics:
    • Real Endpoints specializes in tracking and navigating commercial and private-payer coverage policy and prior-authorization requirements specific to a device category.
  3. HEOR evidence development:
    • Boston Strategic Partners builds the health-economics and outcomes research evidence dossier payers require to justify a coverage or reimbursement decision.

Sources 7 · 0 independent · 7 producer sites

Producers' own sites 7

  1. Mcra producer checked 2026-07-27 · link not kept
  2. Avalere health producer checked 2026-05-12 · link not kept
  3. Boston strategic partners producer checked 2026-06-12 · link not kept
  4. Emergo by ul producer checked 2026-06-02 · link not kept
  5. Real endpoints producer checked 2026-07-30 · link not kept
  6. Health advances producer checked 2026-06-15 · link not kept
  7. Vintura producer checked 2026-05-29 · link not kept